Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics plans multiple September 2026 investor conference appearances with online access to its fireside chat webcasts.
Rhea-AI Summary
Cartesian Therapeutics (RNAC) will participate in three investor conferences in September 2026, including events hosted by Cantor, Morgan Stanley and H.C. Wainwright.
Fireside chats are scheduled for September 10 and 15, 2026, and one-on-one and group investor meetings are planned for September 14, 2026. Live webcasts and limited-time replays of the fireside chats are expected to be available in the Events section of the company’s website.
Positive
- None.
Negative
- None.
Market Reaction – RNAC
Following this news, RNAC has gained 3.18%, reflecting a moderate positive market reaction. The stock is currently trading at $9.37.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
- A fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET on Thursday, September 10, 2026
- One-on-one and group investor meetings at Morgan Stanley’s 24th Annual Healthcare Conference on Monday, September 14, 2026
- A fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference at 1:30 p.m. ET on Tuesday, September 15, 2026
Live webcasts of the fireside chats are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
